DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report published on Monday morning. The firm issued a hold rating on the stock.

Other equities analysts have also recently issued research reports about the stock. HC Wainwright raised their price target on shares of DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, October 24th. JMP Securities reissued a “market outperform” rating and set a $10.00 price target on shares of DBV Technologies in a research report on Tuesday, December 10th.

DBV Technologies Trading Down 3.7 %

DBVT stock opened at $3.09 on Monday. DBV Technologies has a 1-year low of $2.20 and a 1-year high of $10.70. The stock has a 50-day moving average price of $3.44 and a 200-day moving average price of $3.95. The firm has a market cap of $63.56 million, a PE ratio of -0.69 and a beta of 0.64.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.